tbuckley/cabot-search huggingface dataset:
Phase I Clinical Study for Validation of Fimaporfin-Based Photochemical Internalisation: A Novel Technology for Enhancing Cellular Immune Responses Important for Therapeutic Effect of Peptide-and Protein-Based Vaccines
Authors: P.K. Selbo, S. Janetzki, M.J.P. Welters, M. Håkerud, A.G. Nedberg, V.T. Edwards, H. Olivecrona, S.H. van der Burg, T. Otterhaug, A. Hogset
Journal: Annals of Oncology (2019)
The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism
Authors: Michael Heider, Ruth Eichner, Jacob Stroh, Anna Kuisl, Jana Zecha, Jannis Lawatscheck, Martina Rudelius, Anne-Kathrin Garz, Simone Lemeer, Christian Peschel, Ulrich Keller, Katharina Götze, Johannes Buchner, Bernhard Kuster, Vanesa Fernandez-Saiz, Florian Bassermann
Journal: Blood (2019)
Новые возможности немедикаментозного лечения больных с неалкогольной жировой болезнью печени
Authors: N.V. Dragomiretska, I.B. Zabolotna, G.M. Izha
Journal: GASTROENTEROLOGY (2014)

Изложены результаты исследования внутреннего курсового приема водного раствора «Полтавский бишофит» у больных с неалкогольной жировой болезнью печени (НАЖБП). Продемонстрирована эффективность предложенного немедикаментозного лечения данной категории больных в улучшении клинического течения заболевания, восстановлении липидного спектра крови, уменьшении инсулинорезистентности, улучшении течения сопутствующей патологии органов желудочно-кишечного тракта, что патогенетически обосновывает использование водного раствора «Полтавский бишофит» в лечении больных с НАЖБП.
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Authors: Peter Schmid, Jacinta Abraham, Stephen Chan, Duncan Wheatley, Adrian Murray Brunt, Gia Nemsadze, Richard D. Baird, Yeon Hee Park, Peter S. Hall, Timothy Perren, Robert C. Stein, László Mangel, Jean-Marc Ferrero, Melissa Phillips, John Conibear, Javier Cortes, Andrew Foxley, Elza C. de Bruin, Robert McEwen, Daniel Stetson, Brian Dougherty, Shah-Jalal Sarker, Aaron Prendergast, Max McLaughlin-Callan, Matthew Burgess, Cheryl Lawrence, Hayley Cartwright, Kelly Mousa, Nicholas C. Turner
Journal: Journal of Clinical Oncology (2019)

PURPOSE The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. The PAKT trial was designed to evaluate the safety and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC. PATIENTS AND METHODS This double-blind, placebo-controlled, randomized phase II trial recruited women with untreated metastatic TNBC. A total of 140 patients were randomly assigned (1:1) to paclitaxel 90 mg/m 2 (days 1, 8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), PFS and OS in the subgroup with PIK3CA/ AKT1/ PTEN alterations, tumor response, and safety. RESULTS Median PFS was 5.9 months with capivasertib plus paclitaxel and 4.2 months with placebo plus paclitaxel (hazard ratio [HR], 0.74; 95% CI, 0.50 to 1.08; 1-sided P = .06 [predefined significance level, 1-sided P = .10]). Median OS was 19.1 months with capivasertib plus paclitaxel and 12.6 months with placebo plus paclitaxel (HR, 0.61; 95% CI, 0.37 to 0.99; 2-sided P = .04). In patients with PIK3CA/ AKT1/ PTEN-altered tumors (n = 28), median PFS was 9.3 months with capivasertib plus paclitaxel and 3.7 months with placebo plus paclitaxel (HR, 0.30; 95% CI, 0.11 to 0.79; 2-sided P = .01). The most common grade ≥ 3 adverse events in those treated with capivasertib plus paclitaxel versus placebo plus paclitaxel, respectively, were diarrhea (13% v 1%), infection (4% v 1%), neutropenia (3% v 3%), rash (4% v 0%), and fatigue (4% v 0%). CONCLUSION Addition of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS. Benefits were more pronounced in patients with PIK3CA/ AKT1/ PTEN-altered tumors. Capivasertib warrants further investigation for treatment of TNBC.
Adjö — My Patient’s Prolonged Good-Bye
Authors: Uchenna Ikediobi
Journal: New England Journal of Medicine (2019)

"Do you know how to say au revoir in Swedish?" the patient asks. Smiling, the physician pretends she's answering for the first time. She can't help but compare the life of this lonely 95-year-old to those of the respected Igbo elders she knew growing up in Nigeria.
Clinical Benefit of Circulating Tumor DNA Analysis in Follow-up of Patients With Early-Stage Breast Cancer—Reply
Authors: Isaac Garcia-Murillas, Nicholas C. Turner
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
5-AZA treatment induces cytotoxicity and in vitro expression of immunogenic NY-ESO-1 antigen in non-small lung cancer cell NCI-H1975
Authors: V.P. Inchakalody, S. Taleb, S. Sherif, Q. Fernandes, F. Sahir, S.K. Sivaraman, A.Q. Khan, V. Sasidharan Nair, E.A.A. Ashi, L.S. Al-Zaidan, A. Iskandarani, R. Krishnankutty, L. Therachiyil, A. Raza, M. Merhi, S. Uddin, E. Elkord, S. Dermime
Journal: Annals of Oncology (2019)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Authors: Shanu Modi, Cristina Saura, Toshinari Yamashita, Yeon Hee Park, Sung-Bae Kim, Kenji Tamura, Fabrice Andre, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani, Joohyuk Sohn, Neelima Denduluri, Christophe Perrin, Kenjiro Aogi, Eriko Tokunaga, Seock-Ah Im, Keun Seok Lee, Sara A. Hurvitz, Javier Cortes, Caleb Lee, Shuquan Chen, Lin Zhang, Javad Shahidi, Antoine Yver, Ian Krop
Journal: New England Journal of Medicine (2019)

Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation.In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety.Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%).Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).
A recombinant platform for flavivirus vaccines and diagnostics using chimeras of a new insect-specific virus
Authors: Jody Hobson-Peters, Jessica J. Harrison, Daniel Watterson, Jessamine E. Hazlewood, Laura J. Vet, Natalee D. Newton, David Warrilow, Agathe M. G. Colmant, Carmel Taylor, Bixing Huang, Thisun B. H. Piyasena, Weng Kong Chow, Yin Xiang Setoh, Bing Tang, Eri Nakayama, Kexin Yan, Alberto A. Amarilla, Sarah Wheatley, Peter R. Moore, Mitchell Finger, Nina Kurucz, Naphak Modhiran, Paul R. Young, Alexander A. Khromykh, Helle Bielefeldt-Ohmann, Andreas Suhrbier, Roy A. Hall
Journal: Science Translational Medicine (2019)

Insect-specific Binjari virus facilitates the production of chimeric virus particles of flavivirus pathogens for diagnostics and vaccines.
Endoscopic papillary large balloon dilation for pancreatic duct stone: a first report
Authors: Kosuke Iwano, Akira Kurita, Yoshiharu Mori, Shunjiro Azuma, Shujiro Yazumi
Journal: Endoscopy (2019)

A 44-year-old woman, who had been a heavy drinker, was admitted to our hospital for treatment of a pancreatic duct stone with chronic pancreatitis. She had a previous history of endoscopic sphincterotomy for bile duct stones.
TCR engaging antigen-scaffolds for targeted expansion of functionally improved T cells for adoptive cell therapy
Authors: G. Kladis, V. Rafa Mindahl, T. Tamhane, A. Kai Bentzen, M. Donia, I.M. Svane, H. Niessner, T. Sinnberg, C. Garbe, S. Nyboe Jacobsen, C. Schmees, S. Reker Hadrup
Journal: Annals of Oncology (2019)
ABBA the new face of ACID
Authors: Helmut Neumann, Raf Bisschops
Journal: Endoscopy (2019)

In recent years we have seen impressive developments in advanced endoscopic imaging modalities that help us to better diagnose luminal gastrointestinal diseases and guide subsequent (endoscopic) therapy [1]. With the evolution of these new techniques, the responsibility for pathological diagnosis seems to be constantly shifting from the pathologist to the endoscopist.
Efficacy of Mesenchymal Stem Cells in Bronchiolitis Obliterans Syndrome after Allogeneic HSCT: A Multicenter Prospective Cohort Study
Authors: Shan Chen, Ke Zhao, Ren Lin, Shunqing Wang, Zhiping Fan, Fen Huang, Xiaoyong Chen, Danian Nie, Xin Du, Ziwen Guo, Dongjun Lin, Li Xuan, Na Xu, Jing Sun, Andy Peng Xiang, Qifa Liu
Journal: Blood (2019)
Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprograming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept
Authors: Benjamin Watkins, Yvonne Suessmuth, Kayla Betz, Alison Yu, Brandi Bratrude, Muna Qayed, Kathryn Pellegrini, Steven Bosinger, Amelia Langston, John T. Horan, Bruce R. Blazar, Leslie Kean
Journal: Blood (2019)
Efficacy of PI3K inhibitors in advanced breast cancer
Authors: B. Verret, J. Cortes, T. Bachelot, F. Andre, M. Arnedos
Journal: Annals of Oncology (2019)

The phosphoinositide 3 (PI3)-kinase/Akt signaling pathway has always been a focus of interest in breast cancer due to its role in cell growth, cell proliferation, cell migration and deregulated apoptosis. Its activation has been linked to endocrine resistance and worse prognosis in certain subgroups of breast cancer. In addition, deregulation of the PI3K/Akt pathway including PIK3CA activating mutation is frequently present in breast cancer. Multiple efforts have been carried out to target this pathway, initially with pan-PI3K inhibitors with some hint of activity but hampered by their limiting side-effects. A recent large randomized trial in patients with endocrine-resistant PIK3CA-mutant hormone receptor (HR)-positive tumors led to the approval of the first PI3K inhibitor, alpelisib, in combination with fulvestrant. The specificity of alpelisib against the p110α catalytic isoform provided additional efficacy and a better toxicity profile. In this review, we summarize the main research with PI3K inhibitors in breast cancer and we provide some insight of potential future combinations of this treatment in breast cancer patients.
Abstract C21: KRAS confers resistance to mechanical compression in pancreatic cancer cells
Authors: Gregory P. Brittingham, Liam J. Holt
Journal: Cancer Research (2019)

Abstract Physical pressure is fundamentally important for cancer biology, but its effects remain poorly understood. When solid tumors grow confined within surrounding tissue, they build up compressive stress. Given that cells evolved to function in a stable mechanical environment, even slight changes in pressure perturb physiology. Normal cells and early-stage cancer cells stop growing when pressure builds up. In contrast, in advanced cancer, compression can change cellular behavior to drive migration or confer resistance to chemotherapy. This difference implies that cancer cells somehow adapt to physical pressure. Pancreatic ductal adenocarcinoma (PDAC) builds the most compressive stress of any tumor because it grows in the context of a stiff fibrotic microenvironment. We have discovered that KRAS activation, present in &amp;gt;90% PDAC, enables survival under pressure. We propose that the prevalence of KRAS mutation in PDAC is partly due to its role in adaption to the compressive microenvironment in pancreatic tumors. Citation Format: Gregory P. Brittingham, Liam J. Holt. KRAS confers resistance to mechanical compression in pancreatic cancer cells [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2019 Sept 6-9; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2019;79(24 Suppl):Abstract nr C21.
Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation
Authors: Kadriye Nehir Cosgun, Gauri Deb, Xin Yang, Gang Xiao, Teresa Sadras, Jaewoong Lee, Lai N Chan, Kohei Kume, Lu Yang, Huimin Geng, John Chan, Joo Y. Song, Hassan Jumaa, Andrew G. Polson, Hans Clevers, Markus Müschen
Journal: Blood (2019)
Rapid desensitization of humanized mice with anti-human FcεRIα monoclonal antibodies
Authors: Marat V. Khodoun, Suzanne C. Morris, Elizabeth Angerman, Crystal Potter, Richard Schuman, Mark Wunderlich, Joseph J. Maciag, Kathryn C. Sullivan Locker, James C. Mulloy, Andrew B. Herr, Fred D. Finkelman
Journal: Journal of Allergy and Clinical Immunology (2019)
The Pseudomonas aeruginosa accessory genome elements influence virulence towards Caenorhabditis elegans
Authors: Alejandro Vasquez-Rifo, Isana Veksler-Lublinsky, Zhenyu Cheng, Frederick M. Ausubel, Victor Ambros
Journal: Genome biology (2019)

Multicellular animals and bacteria frequently engage in predator-prey and host-pathogen interactions, such as the well-studied relationship between Pseudomonas aeruginosa and the nematode Caenorhabditis elegans. This study investigates the genomic and genetic basis of bacterial-driven variability in P. aeruginosa virulence towards C. elegans to provide evolutionary insights into host-pathogen relationships.Natural isolates of P. aeruginosa that exhibit diverse genomes display a broad range of virulence towards C. elegans. Using gene association and genetic analysis, we identify accessory genome elements that correlate with virulence, including both known and novel virulence determinants. Among the novel genes, we find a viral-like mobile element, the teg block, that impairs virulence and whose acquisition is restricted by CRISPR-Cas systems. Further genetic and genomic evidence suggests that spacer-targeted elements preferentially associate with lower virulence while the presence of CRISPR-Cas associates with higher virulence.Our analysis demonstrates substantial strain variation in P. aeruginosa virulence, mediated by specific accessory genome elements that promote increased or decreased virulence. We exemplify that viral-like accessory genome elements that decrease virulence can be restricted by bacterial CRISPR-Cas immune defense systems, and suggest a positive, albeit indirect, role for host CRISPR-Cas systems in virulence maintenance.
Genomic Mechanisms of Physiological and Morphological Adaptations of Limestone Langurs to Karst Habitats
Authors: Zhijin Liu, Liye Zhang, Zhongze Yan, Zhijie Ren, Fengming Han, Xinxin Tan, Zhiyuan Xiang, Fang Dong, Zuomin Yang, Guangjian Liu, Ziming Wang, Jiali Zhang, Tengcheng Que, Chaohui Tang, Yifeng Li, Song Wang, Junyi Wu, Legong Li, Chengming Huang, Christian Roos, Ming Li
Journal: Molecular Biology and Evolution (2019)

Knowledge of the physiological and morphological evolution and adaptation of nonhuman primates is critical to understand hominin origins, physiological ecology, morphological evolution, and applications in biomedicine. Particularly, limestone langurs represent a direct example of adaptations to the challenges of exploiting a high calcium and harsh environment. Here, we report a de novo genome assembly (Tfra_2.0) of a male François's langur (Trachypithecus francoisi) with contig N50 of 16.3 Mb and resequencing data of 23 individuals representing five limestone and four forest langur species. Comparative genomics reveals evidence for functional evolution in genes and gene families related to calcium signaling in the limestone langur genome, probably as an adaptation to naturally occurring high calcium levels present in water and plant resources in karst habitats. The genomic and functional analyses suggest that a single point mutation (Lys1905Arg) in the α1c subunit of the L-type voltage-gated calcium channel Cav1.2 (CACNA1C) attenuates the inward calcium current into the cells in vitro. Population genomic analyses and RNA-sequencing indicate that EDNRB is less expressed in white tail hair follicles of the white-headed langur (T. leucocephalus) compared with the black-colored François's langur and hence might be responsible for species-specific differences in body coloration. Our findings contribute to a new understanding of gene-environment interactions and physiomorphological adaptative mechanisms in ecologically specialized primate taxa.
Performance of the ESC 0/1-h and 0/3-h Algorithm for the Rapid Identification of Myocardial Infarction Without ST-Elevation in Patients With Diabetes
Authors: Paul M. Haller, Jasper Boeddinghaus, Johannes T. Neumann, Nils A. Sörensen, Tau S. Hartikainen, Alina Goßling, Thomas Nestelberger, Raphael Twerenbold, Jonas Lehmacher, Till Keller, Tanja Zeller, Stefan Blankenberg, Christian Mueller, Dirk Westermann
Journal: Diabetes Care (2019)

Patients with diabetes mellitus (DM) have elevated levels of high-sensitivity cardiac troponin (hs-cTn). We investigated the diagnostic performance of the European Society of Cardiology (ESC) algorithms to rule out or rule in acute myocardial infarction (AMI) without ST-elevation in patients with DM.
Rheological Assessments of Sickle Cell Patients Post Allogeneic Hematopoietic Cell Transplant
Authors: Tami D John, Madeleine Lu, Celeste K. Kanne, Minke A.E. Rab, Richard van Wijk, Sergey S. Shevkoplyas, Vivien A. Sheehan
Journal: Blood (2019)
KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3
Authors: Tian Lan, Hui Li, Delin Zhang, Lin Xu, Hailing Liu, Xiangyong Hao, Xiaokai Yan, Haotian Liao, Xiangzheng Chen, Kunlin Xie, Jiaxin Li, Mingheng Liao, Jiwei Huang, Kefei Yuan, Yong Zeng, Hong Wu
Journal: Molecular Cancer (2019)

Abstract Background N6-methyladenosine (m6A) modification, the most abundant internal methylation of eukaryotic RNA transcripts, is critically implicated in RNA processing. As the largest known component in the m6A methyltransferase complex, KIAA1429 plays a vital role in m6A methylation. However, its function and mechanism in hepatocellular carcinoma (HCC) remain poorly defined. Methods Quantitative PCR, western blot and immunohistochemistry were used to measure the expression of KIAA1429 in HCC. The effects of KIAA1429 on the malignant phenotypes of hepatoma cells were examined in vitro and in vivo. MeRIP-seq, RIP-seq and RNA-seq were performed to identify the target genes of KIAA1429. Results KIAA1429 was considerably upregulated in HCC tissues. High expression of KIAA1429 was associated with poor prognosis among HCC patients. Silencing KIAA1429 suppressed cell proliferation and metastasis in vitro and in vivo. GATA3 was identified as the direct downstream target of KIAA1429-mediated m6A modification. KIAA1429 induced m6A methylation on the 3′ UTR of GATA3 pre-mRNA, leading to the separation of the RNA-binding protein HuR and the degradation of GATA3 pre-mRNA. Strikingly, a long noncoding RNA (lncRNA) GATA3-AS, transcribed from the antisense strand of the GATA3 gene, functioned as a cis -acting element for the preferential interaction of KIAA1429 with GATA3 pre-mRNA. Accordingly, we found that the tumor growth and metastasis driven by KIAA1429 or GATA3-AS were mediated by GATA3. Conclusion Our study proposed a complex KIAA1429-GATA3 regulatory model based on m6A modification and provided insights into the epi-transcriptomic dysregulation in hepatocarcinogenesis and metastasis.
Mitochondrial Haplotype of the Host Stromal Microenvironment Alters Metastasis in a Non-cell Autonomous Manner
Authors: Amanda E. Brinker, Carolyn J. Vivian, Thomas C. Beadnell, Devin C. Koestler, Shao Thing Teoh, Sophia Y. Lunt, Danny R. Welch
Journal: Cancer Research (2019)

Mitochondria contribute to tumor growth through multiple metabolic pathways, regulation of extracellular pH, calcium signaling, and apoptosis. Using the Mitochondrial Nuclear Exchange (MNX) mouse models, which pair nuclear genomes with different mitochondrial genomes, we previously showed that mitochondrial SNPs regulate mammary carcinoma tumorigenicity and metastatic potential in genetic crosses. Here, we tested the hypothesis that polymorphisms in stroma significantly affect tumorigenicity and experimental lung metastasis. Using syngeneic cancer cells (EO771 mammary carcinoma and B16-F10 melanoma cells) injected into wild-type and MNX mice (i.e., same nuclear DNA but different mitochondrial DNA), we showed mt-SNP-dependent increases (C3H/HeN) or decreases (C57BL/6J) in experimental metastasis. Superoxide scavenging reduced experimental metastasis. In addition, expression of lung nuclear-encoded genes changed specifically with mt-SNP. Thus, mitochondrial-nuclear cross-talk alters nuclear-encoded signaling pathways that mediate metastasis via both intrinsic and extrinsic mechanisms. SIGNIFICANCE: Stromal mitochondrial polymorphisms affect metastatic colonization through reactive oxygen species and mitochondrial-nuclear cross-talk.